Drug Trial Radar · NCT04963231
DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway
Last checked: Nov 20, 2026Latest source record: Jul 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
164
Actual
Start
Nov 30, 2021
Primary completion
Aug 4, 2023
Study completion Sep 30, 2024
Sponsor
- Lead sponsor
- Rhythm Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 15, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the safety and efficacy of once daily subcutaneous (SC) administration of setmelanotide in participants with obesity and specific gene variants in the MC4R pathway.
Conditions
- Genetic Obesity
Interventions
SetmelanotideDrug
SC injection
PlaceboDrug
SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Stage 1: Number of Participants by Genotype Who Demonstrated a Significant Clinically Meaningful Response to Setmelanotide at the End of Stage 1Time frame: Baseline to Week 16
Locations
36 sites in 8 countries. Site status is shown where the registry gives one.
HonorHealth Bariatric Center
Scottsdale, Arizona
InQuest Medical Reseacrh
Suwanee, Georgia
UMass Memorial Medical Center
Worcester, Massachusetts
University of Michigan
Ann Arbor, Michigan
Metro Detroit Endocrinology Center
Dearborn, Michigan
Mayo Clinic
Rochester, Minnesota
Mississippi Center for Advanced Medicine
Madison, Mississippi
Mount Sinai
New York, New York
Columbia University
New York, New York
Ten's Medical Center - Pediatric Endocrinology Clinic
Staten Island, New York
University of North Carolina
Chapel Hill, North Carolina
Geisinger Clinic
Danville, Pennsylvania
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Texas Tech
Amarillo, Texas
Endocrine Associates of Dallas and Plano
Dallas, Texas
Hector Granados PA
El Paso, Texas
Texas Children's Hospital
Houston, Texas
Accurate Clinical Research
Houston, Texas
Rio Grande Valley Endocrine Center
McAllen, Texas
Clinical Trials of Texas
San Antonio, Texas
Javara Research
The Woodlands, Texas
University of Alberta
Edmonton, Alberta, Canada
Charite - Universitatsmedizin Berlin
Berlin, Germany
Universitaetsklinikum Leipzig
Leipzig, Germany
Universitaetsklinikum Ulm
Ulm, Germany
University of Patras School of Medicine
Pátrai, Greece
Chaim Sheba MC, Safra Children's Hospital
Ramat Gan, Israel
Erasmus Medisch Centrum
Rotterdam, Netherlands
Hospital Sant Joan de Deu
Barcelona, Spain
Hospital Infantil Universitario Nino Jesus
Madrid, Spain
Hospital Fundación Jimenez Díaz
Madrid, Spain
Hospital General de Valencia
Valencia, Spain
Bristol Royal Hospital for Children
Bristol, United Kingdom
University of Cambridge
Cambridge, United Kingdom
London Medical - The London Diabetes Centre
London, United Kingdom
University College London Hospitals NHS Foundation Trust
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.